MedTrace Logo

To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.

NCT03001726 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 228

Last updated 2022-05-06

No results posted yet for this study

Summary

Investigators assessed the effectiveness of conversional gastrectomy compared with chemotherapy alone following docetaxel, oxalipaltin and S1 therapy for advanced gastric cancer with a single non-curable factor.

Conditions

Interventions

PROCEDURE

Gastrectomy

In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.

DRUG

oxaliplatin

oxaliplatin 100 mg/m2

DRUG

S1

S1 40mg/m2

DRUG

Docetaxel

docetaxel 40 mg/m2

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Tianshu Liu, Physician · Zhongshan Hopital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2022-06-30
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03001726 on ClinicalTrials.gov